中华肝胆外科杂志
中華肝膽外科雜誌
중화간담외과잡지
CHINESE JOURNAL OF HEPATOBILIARY SURGERY
2013年
10期
796-800
,共5页
胰腺肿瘤%受体,表皮生长因子%抗体,单克隆%酪氨酸激酶抑制剂%生物疗法
胰腺腫瘤%受體,錶皮生長因子%抗體,單剋隆%酪氨痠激酶抑製劑%生物療法
이선종류%수체,표피생장인자%항체,단극륭%락안산격매억제제%생물요법
Pancreatic neoplasms%Receptor,epidermal growth factor%Antibodies,monoclonal%Tyrosine Kinase Inhibitors%Biological therapy
胰腺癌因其恶性程度高、预后差而著称,且确诊后手术机会少、化疗效果差.自上世纪末以来,胰腺癌的发病率及死亡人数不断提高,急需有效的治疗方法.人类表皮生长因子受体2是目前研究较多的一个跨膜蛋白,其基因扩增或过表达在胰腺癌发病中起到了促细胞增殖、抑制凋亡、促血管生成等作用.因而针对这一靶点的治疗成为了研究热点:除了已经应用于乳腺癌的曲妥珠单抗外,更有双重抗体、酪氨酸激酶抑制剂等多种以此为靶点的药物被一一发掘.该文就人类表皮生长因子受体2与胰腺癌的关系及以其为靶点的治疗进展进行综述.
胰腺癌因其噁性程度高、預後差而著稱,且確診後手術機會少、化療效果差.自上世紀末以來,胰腺癌的髮病率及死亡人數不斷提高,急需有效的治療方法.人類錶皮生長因子受體2是目前研究較多的一箇跨膜蛋白,其基因擴增或過錶達在胰腺癌髮病中起到瞭促細胞增殖、抑製凋亡、促血管生成等作用.因而針對這一靶點的治療成為瞭研究熱點:除瞭已經應用于乳腺癌的麯妥珠單抗外,更有雙重抗體、酪氨痠激酶抑製劑等多種以此為靶點的藥物被一一髮掘.該文就人類錶皮生長因子受體2與胰腺癌的關繫及以其為靶點的治療進展進行綜述.
이선암인기악성정도고、예후차이저칭,차학진후수술궤회소、화료효과차.자상세기말이래,이선암적발병솔급사망인수불단제고,급수유효적치료방법.인류표피생장인자수체2시목전연구교다적일개과막단백,기기인확증혹과표체재이선암발병중기도료촉세포증식、억제조망、촉혈관생성등작용.인이침대저일파점적치료성위료연구열점:제료이경응용우유선암적곡타주단항외,경유쌍중항체、락안산격매억제제등다충이차위파점적약물피일일발굴.해문취인류표피생장인자수체2여이선암적관계급이기위파점적치료진전진행종술.
Pancreatic cancer (PC) is known for its high malignancy and poor prognosis.Furthermore,PC patients have little chance to receive an operation,and chemotherapy is not always an ideal alternative.More effective treatment is necessary because over the last two decades,the morbidity and the mortality of PC has risen continuously.Some new PC treatments involve HER2,a transmembrane protein that has oncological significance.The amplification of its gene or over expression of itself can cause malignant proliferation,suppression of apoptosis,and angiogenesis in PC.Its potential can be seen with HER2 targeted medicines including the clinically used Trastuzumab,but also with bispecific antibody,tyrosine kinase inhibitors,and more.This article will review the application of these new developments.
